

**Linking Claims**

The Office further indicates that “claim 1 links the inventions of group I that are the individual antisense oligonucleotide sequences listed in claims 24 and 25 ... and also the inventions of claims 26-30.” The Office also states that “[c]laims 1 and 26-30 link the various inventions of claims 24 and 25 that are the individual antisense oligonucleotide sequences listed.” As discussed above, Applicants respectfully assert that no restriction requirement should be applied to claims 24 and 25. Notwithstanding, Applicants note that upon allowance of claim 1 or claims 26-30, the restriction requirement for claims 24 and 25 will be withdrawn. Applicants presume that upon allowance of the linking claims, all sequences listed in claims 24 and 25 will be examined.

**Rejoinder**

The Office notes that process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP §821.04.” (Office Action, page 10). Applicants note that the scope of the non-elected method claims is commensurate to that of the elected product claims and respectfully request the rejoinder of the method claims at the time the pending claims are found to be allowable.


DOCKET NO.: ISIS0124-100 (RTS-0739)  
SERIAL NO.: 10/798,923

PATENT  
FILED: March 10, 2004

**Conclusion**

The examination of the pending claims and passage to allowance are respectfully requested. An early Notice of Allowance is therefore earnestly solicited. Applicants invite the Examiner to contact the undersigned at (215) 665-6904 to clarify any unresolved issues raised by this response.

Respectfully submitted,



\_\_\_\_\_  
**Gwilym John Owen Attwell**  
Registration No. 45,449

Date: **August 20, 2004**

COZEN O'CONNOR  
1900 Market Street  
Philadelphia, PA 19103-3508  
Telephone: (215) 665-6904  
Facsimile: (215) 701-2004

Attachments: Paper Copy of Sequence Listing  
CRF of Sequence Listing  
Statement to Support